Shares of Icon Plc (NASDAQ:ICLR) have received an average rating of “Buy” from the twelve analysts that are covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $163.71.

A number of brokerages recently weighed in on ICLR. BidaskClub upgraded shares of Icon from a “hold” rating to a “buy” rating in a research note on Saturday, July 27th. ValuEngine upgraded Icon from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. KeyCorp boosted their price objective on Icon from $157.00 to $165.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Barclays restated a “hold” rating and set a $154.00 price objective on shares of Icon in a report on Wednesday, April 17th. Finally, Mizuho boosted their price objective on Icon from $160.00 to $170.00 and gave the stock a “buy” rating in a report on Thursday, July 25th.

Shares of ICLR traded down $2.68 during midday trading on Wednesday, hitting $153.35. 235,800 shares of the stock traded hands, compared to its average volume of 280,821. Icon has a 1-year low of $118.10 and a 1-year high of $165.13. The company has a market capitalization of $8.33 billion, a price-to-earnings ratio of 24.38, a PEG ratio of 2.15 and a beta of 0.59. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.07 and a quick ratio of 2.07. The company’s 50 day simple moving average is $154.12.

Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $1.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.01. Icon had a net margin of 13.05% and a return on equity of 25.02%. The company had revenue of $695.14 million during the quarter, compared to the consensus estimate of $693.56 million. During the same quarter in the previous year, the company posted $1.51 earnings per share. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. As a group, equities analysts forecast that Icon will post 6.87 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. SRS Capital Advisors Inc. purchased a new position in Icon during the 2nd quarter valued at about $47,000. Coastal Capital Group Inc. bought a new stake in shares of Icon in the 2nd quarter valued at approximately $78,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Icon in the 2nd quarter valued at approximately $172,000. DekaBank Deutsche Girozentrale grew its stake in shares of Icon by 72.7% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 1,328 shares of the medical research company’s stock valued at $201,000 after buying an additional 559 shares in the last quarter. Finally, H D Vest Advisory Services bought a new stake in shares of Icon in the 2nd quarter valued at approximately $214,000. Hedge funds and other institutional investors own 82.34% of the company’s stock.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Recommended Story: How to track put option volume

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.